Literature DB >> 1829796

[125I]Ifenprodil: a convenient radioligand for binding and autoradiographic studies of the polyamine-sensitive site of the NMDA receptor.

P M Beart1, L D Mercer, B Jarrott.   

Abstract

Iodination of ifenprodil, a non-competitive NMDA antagonist, with Na125I/Chloramin-T gave a radioligand which bound rapidly and saturably to a single population of sites (dissociation constant 145 nM) in membranes of rat cerebral cortex. In competition studies, specific binding of [125I]-ifenprodil was inhibited by analogues of ifenprodil, as well as by spermine and spermidine. Binding was sensitive to Ca2+, Mg2+ and Zn2+. [125I]-Ifenprodil labelled a population of binding sites, which was topographically distributed in rat forebrain, as shown by autoradiography. [125I]Ifenprodil is a useful radioligand for the investigation of the polyamine site of the N-methyl-D-aspartate (NMDA) receptor-complex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829796     DOI: 10.1016/0304-3940(91)90090-g

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones.

Authors:  E J Fletcher; J Church; K Abdel-Hamid; J F MacDonald
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

2.  Blockade by polyamine NMDA antagonists related to ifenprodil of NMDA-induced synthesis of cyclic GMP, increases in calcium and cytotoxicity in cultured neurones.

Authors:  P M Beart; A Schousboe; A Frandsen
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

3.  Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening.

Authors:  Jeff W Hill; Jeffrey F Thompson; Mark B Carter; Bruce S Edwards; Larry A Sklar; Gary A Rosenberg
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.